iloprost and Giant-Cell-Arteritis

iloprost has been researched along with Giant-Cell-Arteritis* in 1 studies

Other Studies

1 other study(ies) available for iloprost and Giant-Cell-Arteritis

ArticleYear
Visual Recovery with Iloprost Added to Corticosteroids in a Case of Giant Cell Arteritis.
    Ocular immunology and inflammation, 2022, Feb-17, Volume: 30, Issue:2

    To date, corticosteroids remain the cornerstone treatment of ocular involvement of GCA, and no other treatment has proven to be effective in this setting. We herein report on a unique case of GCA with ocular involvement worsening despite high dose corticosteroids and recovering with intravenous iloprost.. A 70-year-old man presented with acute vision loss in his left eye related to anterior ischemic optic neuropathy. The diagnosis of giant-cell arteritis was confirmed by a temporal artery biopsy. Despite intravenous pulse methylprednisolone for 3 days then oral prednisone at 60 mg/day, the patient developed from day 5 fluctuating vision loss in the right eye, related to ocular ischemia by occlusion of the ophthalmic artery, and responsive to hyperhydration. Iloprost, an analog of prostacyclin PGI2, was then administered intravenously for 5 days and resulted in a stable improvement in visual acuity in the right eye.. This case highlights the potential role of vasodilatator agents in giant cell arteritis with ocular involvement.

    Topics: Adrenal Cortex Hormones; Aged; Giant Cell Arteritis; Humans; Iloprost; Male; Optic Neuropathy, Ischemic; Temporal Arteries

2022